Tag: non-surgical TGCT therapy

Home / non-surgical TGCT therapy

Categories

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

On February 14, 2025, the Food and Drug Administration sanctioned vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cel...
non-surgical-tgct-therapy

Scan the code